PfSPZ Challenge (NF54)

BIOLOGICAL5 trials

Sponsors

Universitaetsklinikum Tuebingen AöR, Sanaria Inc., University Hospital Tuebingen

Conditions

MalariaMalaria Falciparum

Phase 1

Sequential Optimization of Dose and Schedule of PfSPZ Vaccine

CompletedNCT02704533

Sanaria Inc.Malaria

Start: 2016-08-29End: 2018-12-31Updated: 2019-02-01

Safety and Protective Efficacy of IV Immunization With Cryopreserved PfSPZ Under A/P Chemoprophylaxis

CompletedNCT02858817

University Hospital TuebingenMalaria

Start: 2016-11-28End: 2017-11-16Updated: 2019-07-15

Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults

Not yet recruitingNCT05441410

University Hospital TuebingenMalaria

Start: 2025-06-01End: 2026-06-30Target: 30Updated: 2024-12-06

Safety, Tolerability and Efficacy Against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-naïve Adults

Not yet recruitingNCT06862453

Sanaria Inc.Malaria Falciparum

Start: 2026-03-01End: 2026-12-30Target: 58Updated: 2026-03-23

Phase 2

Antimalarial prophylactic efficacy of a weekly dose atovaquone-proguanil

RecruitingCTIS2024-518884-36-00

Universitaetsklinikum Tuebingen AöRMalaria

Start: 2025-11-12Target: 32Updated: 2026-01-22

Related Papers

The exception that proves the rule: Virulence gene expression at the onset of Plasmodium falciparum blood stage infections

PLoS Pathogens2023-06-2910 citations

A PfSPZ vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infection.

2022-08-2340 citations